Moreover, in the TSC2-WT group, a significant difference was observed in the tumor volume between the palbociclib and combination treatments (F = 1.809, P = 0.001; one-way ANOVA); however, combination therapy showed no significant inhibitory effect over lapatinib monotherapy in this group (F = 2.529, P = 0.0776; one-way ANOVA; Fig. 4b). This evidence concerns the gene TSC2 and neoplasm.